Abstract
Objective: The aim of the study was to investigate the different extent of inhibition of endogenous insulin secretion by the reduction of C-peptide levels in an euglycemic clamp study and its effects on the evaluation of pharmacokinetics, pharmacodynamics of insulin preparations, and quality of clamp study to determine the best reduction range of C-peptide levels. Methods: Healthy Chinese male volunteers were enrolled and underwent a single-dose euglycemic clamp test. Participants were subcutaneously injected with long-acting insulin glargine (0.4 IU/kg). Blood samples were collected pretest and up to 24 h post-test to assess pharmacokinetics (PK), pharmacodynamics (PD), and C-peptide levels. Results: We divided the 39 volunteers enrolled in the study into three groups according to the reduction of C-peptide levels: group A (ratio of C-peptide reduction <30%, n = 13), group B (ratio of C-peptide reduction between ≥ 30% and <50%, n = 15), and group C (ratio of C-peptide reduction ≥50%, n = 11); there were significant differences in the three groups (p = 0.000). The upper and lower limits of blood glucose oscillation in group C was statistically lower than the other groups, the range of oscillating glucose levels in group C was −17.0 ± 6.6% to −1.1 ± 6.7%. The AUC0–24 h in groups A, B, and C were 9.7 ± 2.2, 11.0 ± 2.9, and 11.9 ± 2.1 ng/ml × min, respectively, which indicated an increasing trend in the three groups (P trend = 0.041). For quality assessment, the average glucose (p = 0.000) and MEFTG (p = 0.001) levels in three groups were significantly different. Conclusion: The different extent of inhibition of endogenous insulin will influence the PK/PD of insulin preparations and the quality of the euglycemic clamp. Furthermore, the ratio of C-peptide reduction should be above 50% to free from the interference of endogenous insulin, and the range of blood glucose levels should be consistently maintained at −10% to 0 in the euglycemic clamp.
Highlights
Considering the endogenous insulin and glucose self-regulatory mechanisms, how to precisely evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of insulin preparations has always been a challenge
The hyperinsulinemic-euglycemic clamp technique has been widely used in previous studies, it overestimates the effects of insulin preparations, especially long-acting preparations (Soop et al, 2000; Kim, 2009; James et al, 2020)
We evaluated the quality of the euglycemic clamp by assessing mean glucose levels, standard deviation (SD), coefficient of variation in blood glucose (CVBG), mean excursion from target glucose (MEFTG), and glucose excursion from target range (GEFTR) (Table 4)
Summary
Considering the endogenous insulin and glucose self-regulatory mechanisms, how to precisely evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of insulin preparations has always been a challenge. The hyperinsulinemic-euglycemic clamp technique has been widely used in previous studies, it overestimates the effects of insulin preparations, especially long-acting preparations (Soop et al, 2000; Kim, 2009; James et al, 2020). A previous study using both techniques evaluating the pharmacokinetics of insulin preparations has indicated that artificially established nonphysiological hyperinsulinemia interferes with the PK/PD parameters of insulin preparations (Liu et al, 2019). The euglycemic clamp without exogenous insulin was superior, which is currently used to evaluate the PK/PD of insulin preparations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
